The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
 
Martin Forster
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; Celgene; EQRx; GlaxoSmithKline UK Ltd.; Immutep; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Oxford VacMedix; Pfizer; PharmaMar; Regeneron; Roche; Takeda; Transgene; UltraHuman
Research Funding - Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Achilles Therapeutics; AstraZeneca; Immutep; Janssen Oncology; MSD Oncology; Roche; Takeda
 
Frederic Forget
Consulting or Advisory Role - Merck Serono
Research Funding - Arcagy-Gineco (Inst); AstraZeneca/Daiichi Sankyo (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Immutep (Inst); IQvia (Inst); Janssen (Inst); Labcorp Drug Development (Inst); Macrogenics (Inst); Nouscom (Inst); Panbela Therapeutics (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - Gilead Sciences (Inst); ipsen; Novartis; Teva
 
Serafin Morales Murillo
No Relationships to Disclose
 
Isabel García-Fructuoso
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Eisai; Esteve; Novartis
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis
 
Nuhad Ibrahim
No Relationships to Disclose
 
Omkar Marathe
Employment - The Oncology Institute of Hope and Innovation
Leadership - Clinical trial director; Clinical trial director
Stock and Other Ownership Interests - Anixa Biosciences; ImmunityBio; Nektar; SpringWorks Therapeutics; Summit Therapeutics; Syndax; The Oncology Institute of Hope and Innovation
 
Claus Andrup Kristensen
Honoraria - Merck KGaA
Consulting or Advisory Role - MSD Oncology
Research Funding - Immutep GmbH (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck KGaA; MSD Oncology
 
Simon Laban
Honoraria - Merck Sharp & Dohme (Inst)
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck Sharp & Dohme (Inst)
Speakers' Bureau - Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Peptides for antigen-specific immunotherapy of head and neck cancer or other cancers patent pending
Travel, Accommodations, Expenses - Merck
 
Robert Metcalf
Honoraria - Sanofi
Consulting or Advisory Role - Avacta Life Sciences; Rgenta
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche
 
Julio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; P1 Pratia Oncology; P1 Trials; zogen
Consulting or Advisory Role - Exigent Research Network
Speakers' Bureau - MIBA, Meaningful Insights BioTech Analytics; OnCare Alliance
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); BioNTech (Inst); BostonGene (Inst); BridgeBio Oncology Therapeutics (Inst); Carna Biosciences (Inst); Celcuity (Inst); eFFECTOR Therapeutics (Inst); FibroGen (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); ImmunityBio (Inst); Immutep (Inst); Incyclix Bio (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Medlink (Inst); Medlink (Inst); Merck (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); Ovation Pharma (Inst); Pfizer (Inst); QSAM (Inst); RayzeBio (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Summit Therapeutics (Inst); Synthekine (Inst); Systimmune (Inst); Telix Pharmaceuticals (Inst); Tersera (Inst); Xerient Pharma (Inst)
Travel, Accommodations, Expenses - MIBA, Meaningful Insights BioTech Analytics; OnCare Alliance
 
Hans Wildiers
Consulting or Advisory Role - Agendia (Inst); Agendia (Inst); Ariez International BV (Inst); Astrazeneca (Inst); AstraZeneca NV/SA (Inst); Augustine Therapeutics (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Belgium N.V.-S.A. (Inst); Daiichi Sankyo Europe GmbH; Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eli Lily Benelux N.V. (Inst); Gilead Sciences (Inst); Gilead Sciences Belgium BV/SRL (Inst); Immutep (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); MediMix bv (Inst); MediMix BV (Inst); Menarini (Inst); Menarini Stemline Benelux NV/S.A. (Inst); Novartis (Inst); Novartis Pharma NV (Inst); NV Hict (Inst); Pfizer (Inst); PSI (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences (Inst); Gilead Sciences (Inst)
 
Frederik Marmé
Honoraria - AGENDIA; AstraZeneca; Böhringer-Ingelheim; Clovis Oncology; Daiichi Sankyo; Eisai; Genomic Health; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Immunogen; Immunomedics (Inst); Lilly; Menarini Group; MSD Oncology; Myriad Genetics; NIONTECH; Novartis; Novocure; Pfizer; Pharma&; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca (Inst); Biontech; Böhringer-Ingelheim; Clovis Oncology; CureVac; Eisai; Genomic Health; German Breast Group; Gilead Sciences; Gilead Sciences; Gilead Sciences (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Immunomedics (Inst); INCYTE (Inst); Myriad Genetics; Myriad Genetics (Inst); Nerviano Medical Sciences; Pfizer; Pharma&; Roche (Inst); Seagen; Stemline Menarini; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Menarini Group; Pfizer; Roche
 
Irene Brana
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim Spain; Cancer Expert Now; Gilead Sciences; Merck Sharp & Dohme; Merus; Pyxis; Pyxis
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD
Research Funding - AOP Health (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Pharma (Inst); IDEAYA Biosciences (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pyxis (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); SERVIER (Inst); Shattuck Labs (Inst); Tango Therapeutics (Inst); Tolremo (Inst); VCN Biosciences (Inst)
 
Christian Mueller
Employment - Immutep
Stock and Other Ownership Interests - Bayer; Immutep
 
Chrystelle Brignone
Employment - Immuep SAS
Stock and Other Ownership Interests - Immutep
 
Frederic Triebel
Employment - Immutep
Leadership - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-03 owned by Immutep SAS